Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes
Authors' conclusion
Semaglutide and MBS were both associated with improvements in weight and improved glycaemic control at 2 years after the start of the intervention, but MBS was associated with better weight loss and glucometabolic control.
Study context
- Population
- Patients with T2D and obesity in Sweden, Scandinavian Obesity Surgery Registry and National Diabetes Registry, treatment started 2018–2020matched cohort
- Participants
- 606 vs 997
- Exposure
- Metabolic and bariatric surgery (MBS) vs semaglutide
- MBSn = 606
- Semaglutiden = 997reference
- Outcome
- Weight loss and glycaemic control
- Follow-up
- 2 years
Methodological detailspropensity score matching (1:1-2), adjusted for glomerular filtration rate and body mass index
- Propensity score matching (1:1-2)
- Adjusted for glomerular filtration rate and body mass index
Main finding
As reported in the abstract
HbA1c
MBS
42.3
mean · ± 11.18
Semaglutide
50.7
mean · ± 12.48
P < 0.001
Observational data: associations, not effects.
Further findings
Complete remission without other treatment than the intervention · 2 years
P < 0.001
Total weight loss · 2 years
P < 0.001
Original publication
Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes. Diabetes Obes Metab. Published 18 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →